Current Report Filing (8-k)
September 27 2021 - 8:11AM
Edgar (US Regulatory)
0001314052
false
0001314052
2021-09-27
2021-09-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): September 27, 2021
ANAVEX LIFE SCIENCES CORP.
(Exact name of registrant as specified
in its charter)
Nevada
|
001-37606
|
98-0608404
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
51 West 52nd Street
7th Floor
New York, NY USA 10019
(Address of principal executive offices) (Zip Code)
|
1-844-689-3939
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title
of Each Class
|
|
Trading
Symbol
|
|
Name
of Each Exchange on Which Registered
|
Common
Stock, par value $0.001 per share
|
|
AVXL
|
|
The
Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On September 21,
2021, Anavex Life Sciences Corp., a Nevada corporation (the “Company”) received an approval letter from The
Nasdaq Stock Market LLC approving the Company’s application to list the Company’s common stock, par value $0.001 per
share (the “Common Stock”), on the Nasdaq Global Select Market. Shares of the Company’s Common Stock were
previously listed on the Nasdaq Capital Market. The Company’s Common Stock is expected to begin trading on the Nasdaq Global
Select Market under its current ticker symbol, “AXVL”, as of market open September 27, 2021.
On September 27,
2021, the Company issued a press release (the “Press Release”) announcing the commencement of trading of its
Common Stock on the Nasdaq Global Select Market. A copy of the Press Release is attached to this Current Report on Form 8-K as
Exhibit 99.1 and incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
ANAVEX LIFE SCIENCES CORP.
|
|
|
|
By:
|
/s/Christopher Missling
|
|
|
Name:
Christopher Missling, PhD
Title: Chief Executive Officer
|
Date: September 27, 2021
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Sep 2023 to Sep 2024